Intangible Assets and Goodwill (Tables)

9 Months Ended

Sep. 29, 2019

Goodwill and Intangible Assets Disclosure [Abstract]



(Dollars in Millions)	September 29, 2019		December 30, 2018
Intangible assets with definite lives:
Patents and trademarks — gross	$	36,114	35,194
Less accumulated amortization	12,158		9,784
Patents and trademarks — net	23,956		25,410
Customer relationships and other intangibles — gross	21,845		21,334
Less accumulated amortization	9,120		8,323
Customer relationships and other intangibles — net	12,725		13,011
Intangible assets with indefinite lives:
Trademarks	6,875		6,937
Purchased in-process research and development ⁽¹⁾	4,290		2,253
Total intangible assets with indefinite lives	11,165		9,190
Total intangible assets — net	$	47,846	47,611

⁽¹⁾In the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter of 2018 related to the development program of AL-8176. In the fiscal second quarter of 2019, the Company completed the acquisition of Auris Health, Inc. and recorded an in-process research and development intangible asset of $2.9 billion.

Goodwill

Goodwill as of September 29, 2019 was allocated by segment of business as follows:



(Dollars in Millions)	Consumer			Pharm		Med Devices		Total
Goodwill at December 30, 2018	$	8,670		9,063		12,720		30,453
Goodwill, related to acquisitions	1,191			—		2,018		3,209
Currency translation/Other	(266		)	(86	)	(19	)	(371	)
Goodwill at September 29, 2019	$	9,595		8,977		14,719		33,291